Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

• Główni autorzy: Martin Štach (Autor), Robert Pytlík (Autor), Kristýna Šmilauerová (Autor), Jana Rychlá (Autor), Martin Mucha (Autor), Jan Musil (Autor), Abhishek Koladiya (Autor), Matěj Nemec (Autor), Martina Petráčková (Autor), Iva Kaštánková (Autor), Pavla Pecherková (Autor), Lucie Šrámková (Autor), Kamila Polgárová (Autor), Marek Trněný (Autor), Petr Lesný (Autor), Jan Vydra (Autor), Pavel Otáhal (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-clin...